Ferrostatin-1 NEW
| Price | $59 | $89 | $189 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-17 |
Product Details
| Product Name: Ferrostatin-1 | CAS No.: 347174-05-4 |
| Purity: 99.30% | Supply Ability: 10g |
| Release date: 2026/07/17 |
Product Introduction
Bioactivity
| Name | Ferrostatin-1 |
| Description | Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of iron death. Ferrostatin-1 potently inhibits Erastin-induced iron death in HT-1080 cells with an EC50 of 60 nM. Ferrostatin-1 also exhibits antioxidant and antifungal activities. |
| Cell Research | Cell viability was typically assessed in 384-well format by Alamar Blue fluorescence (ex/em 530/590) measured on a Victor3 plate reader. In some experiments, Trypan Blue dye exclusion counting was performed using an automated cell counter. Cell viability under test conditions is reported as a percentage relative to the negative control treatment [1]. |
| In vitro | METHODS: Human bronchial epithelial cells BEAS-2B were co-treated with LPS (10 mg/L) and Ferrostatin-1 (2 μM) for 16 h. The growth inhibition of the cells was detected by CCK-8 method. RESULTS: Ferrostatin-1 attenuated the LPS-induced cell damage. [1] METHODS: Human fibrosarcoma cells HT-1080 were treated with Ferrostatin-1 (0.5 μM) and Erastin (10 μM) for 4 h, and ROS levels produced by the cells were measured by Flow Cytometry. RESULTS: Ferrostatin-1 inhibited the Erastin-induced accumulation of cytoplasmic and lipid ROS. [2] METHODS: Mouse hippocampal neuronal cells HT-22 were treated with Ferrostatin-1 (3-12 μM) for 16 h, then treated with 5 mM glutamate for 24 h, and then LDH release was measured. RESULTS: The release of LDH was significantly increased by treatment with glutamate, and the release of LDH was inhibited by Ferrostatin-1 treatment. [3] |
| In vivo | METHODS: To investigate whether iron death is associated with LPS-induced acute kidney injury (AKI), Ferrostatin-1 (5 mg/kg) was administered intraperitoneally in a single dose to C57BL/6 mice, and infectious AKI was induced by intraperitoneal injection of LPS (10 mg/kg) 30 min later. RESULTS: Ferrostatin-1 significantly protected mice from renal dysfunction and tubular injury in LPS-induced AKI. [4] METHODS: To investigate whether iron disorders are associated with acute liver disease and its molecular mechanism, Ferrostatin-1 (2.5 μM/kg) was intraperitoneally injected into ICR mice once a day for three days, followed by intraperitoneal injection of TAA (250 mg/kg/day) for three consecutive days, to establish an acute liver injury (ALI) model in mice. RESULTS: Ferrostatin-1 pretreatment significantly reduced TAA-induced changes in plasma ALT, AST and LDH levels, inhibited the expression of TfR1, Fpn and Ft-L proteins, and decreased iron accumulation without affecting the expression of xCT or GPX4 in the liver. Ferrostatin-1 prevents hepatic iron by decreasing death. [5] |
| Storage | Keep away from direct sunlight, Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 26.2 mg/mL (99.87 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 20 mg/mL (76.23 mM), Suspension. DMSO : 237.5 mg/mL (905.28 mM), Sonication is recommended. |
| Keywords | ROS | neurotoxicity | Inhibitor | inhibit | Fungal | Ferrostatin-1 | Ferrostatin1 | Ferroptosis | Fer-1 | Fer1 | Fer 1 | death | cytosolic | cell | antioxidant | antifungal |
| Inhibitors Related | Calcium Propionate | Dehydroacetic acid sodium | Hemin | Terbinafine hydrochloride | Benzyl propionate | L-Glutamic acid | Sodium formate | Magnesium acetate tetrahydrate | Geraniol | L-Cystine | L-Glutamine | Sodium Molybdate |
| Related Compound Libraries | Apoptosis Compound Library | Ferroptosis Compound Library | Bioactive Compound Library | Anti-Fungal Compound Library | Antioxidant Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Metabolism Disease Compound Library | Oxidation-Reduction Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $100.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
|
VIP5Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2026-07-17 | ||
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2019-12-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY